Table 3.
Comparison of mean changes from baseline in biomarkers between treatment and control groups.
| aMepolizumab13 | Omalizumab14 | bDupilumab15,17 | Mepolizumab16 | ||
|---|---|---|---|---|---|
| Blood Eosinophils | Reduced (p < 0.001) | NR | Not significant (Temporary increase in some patients) | Reduced (Baseline mean 500 cells/ml drop to 50 cells/ml EoT) | |
| Plasma eotaxin-3 | NR | NR | Reduced (p < 0.001) | NR | |
| Serum | Total IgE | NR | Complex | Reduced (p < 0.001) | NR |
| ECP | Reduced (p = 0.022) | NR | NR | NR | |
| IL-5Rα | Reduced (p < 0.001) | NR | NR | NR | |
| TARC | NR | NR | Not significant | NR | |
| Nasal Secretions | Total IgE | Not significant | NR | Reduced (p < 0.05) | NR |
| ECP | Not significant | NR | Not significant | NR | |
| IL-1β | Reduced (p = 0.043) | NR | NR | NR | |
| IL-5 | Not significant | NR | NR | NR | |
| IL-5Rα | Reduced (p = 0.010) | NR | NR | NR | |
| IL-6 | Reduced (p = 0.020) | NR | NR | NR | |
| MPO | Reduced (p = 0.009) | NR | NR | NR | |
| Eotaxin-3 | NR | NR | Reduced (p < 0.001) | NR | |
| Nasal polyp tissue | Total IgE | NR | NR | Reduced (not significant) | NR |
| IL-13 | NR | NR | Reduced (not significant) | NR | |
| ECP | NR | NR | Reduced (p < 0.01) | NR | |
| PARC | NR | NR | Reduced (p < 0.01) | NR | |
| Eotaxin-1 | NR | NR | Reduced (p < 0.05) (Not significant from baseline) | NR | |
| Eotaxin-2 | NR | NR | Reduced (not significant) | NR | |
| Eotaxin-3 | NR | NR | Reduced (not significant) | NR | |
ECP, eosinophil cationic protein; NR, non reported; IL, interleukin; IL-5R α, IL-5 receptor α subunit; TARC，Thymus and Activation-Regulated Chemokine; PARK, pulmonary and activation-regulated chemokine; IL-1β, IL-1β subunit; MPO, myeloperoxidase. NR, not reported.
a
Because of the dropouts, the shown data of this study were all last-observation-carried-forward imputation (LOCF) results.